[redactions made under s47F of the FOI Act]
Hours:Tue‐Fri nhmrc.gov.au
I acknowledge the Traditional Custodians of the lands around Australia and pay my respects to Elders past and present.
From: Mark Bellgrove <xxxx.xxxxxxxxx@xxxxxx.xxx>
Sent: Thursday, 9 April 2020 8:06 AM
To: Clinical Guidelines <xxxxxxxxxxxxxxxxxx@xxxxx.xxx.xx>; Admin <xxxxx@xxxxx.xxx.xx>
Cc:
Subject: Re: ADHD Guidelines [SEC=OFFICIAL]
Dear Sally, many thanks for providing this advice,
We are experiencing some delays associated with COVID-19 but are still tracking ok I think.
We will certainly provide updates on timelines etc
Sincerely
Mark Bellgrove
On Wed, 8 Apr 2020 at 21:36, Clinical Guidelines <xxxxxxxxxxxxxxxxxx@xxxxx.xxx.xx>
wrote:
Dear
Just a quick note to provide you with some general information about the approval process.
Most of this information you’re probably familiar with but I thought I might go over it in case
anything is new since the last time you submitted a guideline for approval. I will also touch
base closer to the time that the requirements are due.
To be approved a guideline must meet the
NHMRC guideline standard and follow the
Procedures and requirements for meeting the NHMRC standard for guidelines.
NHMRCCouncilMeetings
Although there are changes to other NHMRC Committees due to the COVID-19 pandemic, we
understand the Council meetings will still go ahead as planned. The planned dates for 2021 are
11 March and 17 June. The third date for 2021 is to be advised and is most likely to be held in
October or November.
Council will be asked to consider the guideline recommendations only and the public
consultation report. All other material (the full guidelines, the technical and administrative
reports etc) will still need to be submitted to NHMRC and may be examined by Council if it
requests it. We will ask that someone from the guideline development group be available, in
person or by video, to answer any questions Council members may have. If Council are happy
2
then formal confirmation of CEO approval of your guidelines will be sent no more than three
weeks after the meeting.
Progressreport
I have attached the progress report template for you to complete and return to NHMRC – this
is should be done 3-6 months before public consultation begins.
Publicconsultation
I have attached the NHMRC advice on public consultation for you. The main thing to stress is
the importance of sending the draft guidelines to all CEOs, Secretaries or Directors General of
state and territory health departments, explicitly inviting them to make a response. This step
mitigates the risk of the states and territories voicing concerns later on when it is too late to
change the guidelines, and also helps reassure members of council representing states and
territories. We also advise individual NHMRC council members about public consultation and
invite them to make a submission in their individual capacities.
ExpertPeerReviewNames
I would appreciate you providing me with the names of six people whom we can approach to
provide expert peer review of the draft guidelines, so that we can contact them well ahead of
time. They should be experts in part or all of the guidelines’ subject matter, not involved in
their development and preferably a mix of both international and Australian experts. NHMRC
will also independently source a similar number of experts (noting that the response rate for
timely expert review is usually poor, so the more people who are approached the greater the
possibility of getting reviews back in the required time).
MethodologicalReview
Please find attached a methodological review template for you to complete and submit to
NHMRC together with the draft guideline. You will see the template asks you to identify
whereabouts in the guideline various pieces of information can be found.
As ever we would appreciate a heads up if the guidelines are likely to be controversial or if
Commonwealth ministers are likely to be lobbied because of anything in them.
Happy to discuss anything here if you need more information. Have a great Easter break and
stay well.
Kind regards,
Sally
Sally Wright
Project Officer, Clinical Practice Guidelines
Research Translation
National Health and Medical Research Council
xxxxx.xxxxxx@xxxxx.xxx.xx
+61 03 8866 0411
Hours:Tue‐Fri
nhmrc.gov.au
3
On 11/02/2020 12:18 pm, Clinical Guidelines wrote:
Hi
Thanks for the update. My response is added below.
Best wishes,
Sally
Sally Wright
Project Officer, Clinical Practice Guidelines
Research Translation
National Health and Medical Research Council
xxxxx.xxxxxx@xxxxx.xxx.xx
+61 03 8866 0411
nhmrc.gov.au
I acknowledge the Traditional Custodians of the lands around Australia and pay my respects to Elders
past and present.
From:
Sent: Thursday, 23 January 2020 11:06 AM
To: Clinical Guidelines <xxxxxxxxxxxxxxxxxx@xxxxx.xxx.xx>
Subject: Re: ADHD Guidelines [SEC=OFFICIAL]
Hi Sally,
My apologies for such a delayed response. I hope you had a lovely festive
season.
In response to your points:
5
How are you? I unfortunately missed the first
meeting between NHMRC and AADPA so just touching
base on some of the details discussed and the next
steps.
* You were noted as being the primary
contact. Is it ok for me to email you directly
with questions and updates or would you like me to
CC in other members of the guideline development
group?
* The conflict of interest and Aboriginal
and Torres Strait Islander 'Guidelines for
Guidelines' modules were noted in the discussion
minutes. Is this something we mentioned in passing
or would you like a copy of the module if it is
available?
* Just confirming the date February 2021 is
for public consultation of the draft guideline and
June 2021 is submission of the draft guideline to
NHMRC Council? Are you considering 30 or 60 days
for your public consultation? It's ok if these
dates are not locked in. I will touch base again
regarding any date changes and the progress report
a few months prior to PC.
* A public consultation process was noted
for the questions in scope. Is this something
you're planning for next year?
Thanks very much
and apologies for missing
the first meeting. If you have any questions
please don't hesitate to contact me via the
clinical guidelines mailbox
xxxxxxxxxxxxxxxxxx@xxxxx.xxx.xx<mailto:clinicalgui
xxxxxxx@xxxxx.xxx.xx> or directly on 03 8866 0411.
Kind regards,
Sally
Sally Wright
Project Officer, Clinical Practice Guidelines
Research Translation
National Health and Medical Research Council
xxxxx.xxxxxx@xxxxx.xxx.xx
+61 03 8866 0411
nhmrc.gov.au
[Logo-inline-tagline-purple]
I acknowledge the Traditional Custodians of the
lands around Australia and pay my respects to
Elders past and present.
[cid:image001.gif@01D46089.791BAD30]
This email (including any attached files) is
intended only for the addressee, it may contain
confidential information. If you are not the
7
addressee, you are notified that any transmission,
distribution, printing or duplication of this
email is strictly prohibited. If you have received
this email in error please promptly inform the
sender and delete all copies of this e-mail and
all attachments.
Unless explicitly attributed, the opinions
expressed do not necessarily represent the
official position of the National Health and
Medical Research Council.
Please consider the environment before printing
this email, thank you.
This email (including any attached files) is intended only for
the addressee, it may contain confidential information. If you
are not the addressee, you are notified that any transmission,
distribution, printing or duplication of this email is
strictly prohibited. If you have received this email in error
please promptly inform the sender and delete all copies of
this e-mail and all attachments.
Unless explicitly attributed, the opinions expressed do not
necessarily represent the official position of the National
Health and Medical Research Council.
Please consider the environment before printing this email,
thank you.
This email (including any attached files) is intended only for the
addressee, it may contain confidential information. If you are not the
addressee, you are notified that any transmission, distribution, printing
or duplication of this email is strictly prohibited. If you have received
this email in error please promptly inform the sender and delete all
copies of this e-mail and all attachments.
Unless explicitly attributed, the opinions expressed do not necessarily
represent the official position of the National Health and Medical
Research Council.
Please consider the environment before printing this email, thank you.
--
PROFESSOR MARK A. BELLGROVE
Director of Research, Turner Institute for Brain and Mental Health
National Health and Medical Research Council (NHMRC) Senior Research Fellow
President, Australian ADHD Professionals Association (AADPA) Ltd
Turner Institute for Brain and Mental Health
School of Psychological Sciences
Monash University
Room 540, 18 Innovation Walk
Clayton Campus, Clayton VIC 3800
Australia
T:
E: xxxx.xxxxxxxxx@xxxxxx.xxx
ORCID: orcid.org/0000-0003-0186-8349
http://www.monash.edu.au/research/profiles/profile.html?sid=1985044&pid=6456
http://www.monash.edu/turner-institute/
I acknowledge the Traditional Owners and Custodians of the lands on which I live and work and pay my respect to
Elders both past and present
This email (including any attached files) is intended only for the
addressee, it may contain confidential information. If you are not the
addressee, you are notified that any transmission, distribution, printing
or duplication of this email is strictly prohibited. If you have received
this email in error please promptly inform the sender and delete all
copies of this e-mail and all attachments.
8
Unless explicitly attributed, the opinions expressed do not necessarily
represent the official position of the National Health and Medical
Research Council.
Please consider the environment before printing this email, thank you.
9
